Menu Search
Equities

Peptonic Medical AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
28L:FRA

Peptonic Medical AB

Actions
  • Price (EUR)0.0016
  • Today's Change0.001 / 700.00%
  • Shares traded1.00m
  • 1 Year change+788.89%
  • Beta0.4202
Data delayed at least 15 minutes, as of Feb 06 2026 07:18 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company's main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.

  • Revenue in SEK (TTM)15.69m
  • Net income in SEK-48.98m
  • Incorporated2009
  • Employees3.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.